Referral Center for Sickle Cell Disease, CHIC Hospital, Créteil, France.
Hematol Oncol Stem Cell Ther. 2020 Sep;13(3):121-130. doi: 10.1016/j.hemonc.2019.12.002. Epub 2020 Mar 12.
Cerebral vasculopathy is the most severe complication affecting children with sickle cell anemia. Significant progress has been made in the management of sickle cell anemia cerebral vasculopathy, including early transcranial Doppler screening, chronic transfusion, andhydroxyurea. Nevertheless, for patients with a potential matched-sibling donor (MSD), stem cell transplantation (SCT) is now the treatment offering the best cerebral vasculopathy outcome. In the absence of MSD,alternative SCT should be recommended only in those with worsening cerebral vasculopathy despite standard treatments, and should be limited to related haplo-identical SCT undertaken in controlled studies.
脑血管病是影响镰状细胞贫血儿童的最严重并发症。镰状细胞贫血性脑血管病的治疗已取得显著进展,包括早期经颅多普勒筛查、慢性输血和羟基脲治疗。然而,对于有潜在匹配供体(MSD)的患者,干细胞移植(SCT)现在是提供最佳脑血管病结果的治疗方法。在没有 MSD 的情况下,仅应在标准治疗后脑血管病恶化的患者中推荐替代 SCT,并且应仅限于在对照研究中进行的相关半相合同种异体 SCT。